It improves how efficiently your body processes glucose after meals
It is the very activity that affects chromosomal end maintenance in laboratory models
Keywords MC4R deficiency , genetic obesity , GLP-1 receptor agonists , leptin-melanocortin pathway , weight management 0 1 INTRODUCTION Genetic obesity is broadly divided into syndromic obesity and non-syndromic obesity, both of which can be caused by monogenic, polygenic, or chromosomal abnormalities [1]
Weight loss Available in NZ = Liraglutide high dose (Saxenda, daily injection) Self-funding needed ($500-600/month) Not available in NZ = Semaglutide (Ozempic, Wegovy) or Tirzepatide (Mounjaro), as of May 2023 Side effects, particularly upper gastrointestinal, are common with GLP-1 agonist initiation
Science goes against these approaches